| |
May 1 - 3, 2023 | Jersey City, NJ Connect with senior executives in Medical Affairs, MSL and IIT to share best practices. Save $200 when you register today!
|
|
| By Annalee Armstrong,Max Bayer,Gabrielle Masson Silicon Valley Bank’s capital raise of $2 billion has sent shock waves across the biotech industry and spurred a panic among some top venture capital firms that are urging their companies to withdraw deposits. |
|
|
|
By Ben Adams Last year, it was a slap that shook the Oscars. This year, it’s a jab: a “skinny jab,” to be exact, as Ozempic gets its name in lights. |
By Fraiser Kansteiner,Eric Sagonowsky,Zoey Becker,Kevin Dunleavy,Angus Liu The Fierce Pharma team didn't want AbbVie's Humira to have the entire patent-cliff spotlight this year, so we're presenting this special report on the top U.S. losses of exclusivity in 2023. Besides Humira, drugs from J&J, AstraZeneca and more make the list. |
By James Waldron The latest fear stalking biotech boardrooms isn’t a trial fail or an underwhelming funding haul, it’s the postman delivering a letter from Nasdaq warning that the company’s stock faces being delisted from the stock exchange. |
|
Thursday, March 23, 2023 | 10am ET / 7am PT In this webinar, we will discuss customer-centric digital innovations that are improving overall process, product quality and performance, as well as transforming CDMO relationships. Register now to learn more!
|
|
By Andrea Park Right on schedule, PerkinElmer has completed the split it announced last August, selling off its applied science, food and enterprise services businesses to private equity firm New Mountain Capital and combining the remaining life sciences and diagnostics businesses into a new, standalone company. |
By Teresa Carey This week on "The Top Line," we discuss the SBV failure, what to expect next and what it all meant for the biotech industry. We also cover Pfizer's big acquisition, insulin prices and more of this week's top headlines. |
By Kevin Dunleavy Scoring two of the three largest M&A deals in biopharma last year was just an appetizer for Pfizer. On Monday, the industry giant sat down to the main course, gobbling up Seattle cancer specialist Seagen for $43 billion. It is the largest acquisition in biopharma since June of 2019, when AbbVie acquired Allergan for $63 billion. |
By James Waldron An antibody-drug conjugate that GSK paid $100 million to license from Mersana Therapeutics has been slapped with a clinical hold after a patient died in the therapy’s first trial. |
By Zoey Becker GSK's combination MenABCWY vaccine has been in the works for years, but always running slightly behind Pfizer's rival shot. Now, in a phase 3 trial, the GSK shot proved itself against GSK's approved meningitis vaccines Bexsero and Menveo. |
By Andrea Park A study published in the journal Respiratory Care this month found that University of Cincinnati startup PEP Buddy’s eponymous device significantly improved COPD patients’ breathlessness caused by physical activity. |
By Kevin Dunleavy Pfizer is the runaway winner of the United States’ first quarterly Who Can Raise Prices Higher Than the Rate of Inflation contest. Among 27 medicines whose price hikes exceeded the rate of inflation in the fourth quarter of 2022, Pfizer had five, which was three more than any other company. The list was released by the White House on Wednesday. |
By Helen Floersh Projects by teams from Stanford University and Johns Hopkins University will be part of the payload March 14 on SpaceX CRX-27, a resupply mission to the International Space Station. The researchers hope to leverage aging effects of microgravity on heart muscle cells to ultimately help identify new treatments for cardiovascular disease. |
By Andrea Park Illumina is reportedly the target of an upcoming proxy battle, stemming from the sequencing giant’s decision to plow ahead in its $8 billion reacquisition of former spinout Grail in 2021 in defiance of regulators. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we take on AI and machine learning in the pharma and healthcare universe. The expectation is that these tools will speed up innovation and open up new markets, helping the sector stay ahead of the curve. Plus, this week's headlines. |
|
|---|
|
|
|
Wednesday, March 29, 2023 | 2pm ET / 11 am PT Attendees will come away with a deeper understanding of how genetic counseling and genetic services workflows can help biopharma organizations more effectively identify patients that qualify for their clinical trials and/or commercial therapeutics, the value of customized genetic services workflows in optimizing clinical trial/sponsored testing program ROI, and more. Register now.
|
|
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperGet access to the latest life sciences intelligence and stay ahead of the game using Ferma.AI Sponsored by: Ferma.AI, a Product of ZoomRx |
| WhitepaperLearn how HCP statements influence patient decisions Sponsored by: ZoomRx - HCP-Patient Dialogue Research |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| Whitepaper Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
